Company Filing History:
2 out of 8 
2 out of 3,923 
Years Active: 2021
Title: The Innovations of Stephen Canham
Introduction
Stephen Canham is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of immunology through his innovative work on locked nucleic acid cyclic dinucleotide compounds. With a total of 2 patents, Canham's inventions focus on enhancing immune responses.
Latest Patents
Canham's latest patents include groundbreaking technologies that provide highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators. These stimulators activate dendritic cells (DCs) via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). The first patent details a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production. The cyclic dinucleotides in this composition contain at least one 2', 4′ locked nucleic acid. The second patent presents compositions and methods for activating STING-dependent signaling, utilizing cyclic purine dinucleotides that are mono- or di-fluoro substituted.
Career Highlights
Throughout his career, Stephen Canham has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notable organizations include Chinook Therapeutics, Inc. and Novartis AG. His work in these companies has contributed to advancements in therapeutic strategies and immune modulation.
Collaborations
Canham has collaborated with esteemed colleagues such as David Braun Kanne and Jeffrey McKenna. These partnerships have fostered a collaborative environment that enhances innovation and research in the field.
Conclusion
Stephen Canham's contributions to immunology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to influence the development of immune stimulators and therapeutic strategies.